TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28615090

Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling during OGTT after rest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling during OGTT after exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISIMatsuda after rest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISIMatsuda after exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISICederholm after rest
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arterialised blood sampling for ISICederholm after exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Venous blood sampling
Number of subjects: 10
Study: 25439604

Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens (CL) correction
Number of subjects: 114
Study: 24107881

Group type: EXPERIMENTAL
Intervention: Psychosocial group therapy (PST) for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychosocial group therapy (PST)
Number of subjects: 0
Study: 22075098

Group type: EXPERIMENTAL
Intervention: escitalopram plus placebo
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: bupropion sustained release (SR) plus escitalopram
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: venlafaxine extended release (XR) plus mirtazapine
Number of subjects: 665

Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 665
Study: 20209977

Group type: EXPERIMENTAL
Intervention: Acupuncture-assisted anesthesia (AAA) group: electroacupuncture (EA, 2 Hz/100 Hz, 9 mA) applied to Changqiang (GV 1) and Yaoshu (GV 2) for 20 min, and 1% lidocaine (5 mL) injected into GV 1.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group: 20 mL and 10 mL of 1% lidocaine injected into GV 2 and GV 1, respectively.
Number of subjects: 40
Study: 16978077

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole
Number of subjects: 531

Group type: COMPARATOR
Intervention: Ceftriaxone plus metronidazole
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 531
Study: 15531054

Group type: EXPERIMENTAL
Intervention: Patella alta group during fast walking
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pain-free controls during fast walking
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patella alta group during normal walking
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pain-free controls during normal walking
Number of subjects: 24
Study: 11551092

Group type: EXPERIMENTAL
Intervention: Outreach clinics
Number of subjects: 324

Group type: COMPARATOR
Intervention: Main base clinics
Number of subjects: 324
Study: 10196816

Group type: EXPERIMENTAL
Intervention: Anterior-inferior mandibular osteotomy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Somnographic registration (apnea index, apnea/hypopnea index, oxygen desaturation index) and cephalometric analysis
Number of subjects: 10
Study: 8001520

Group type: EXPERIMENTAL
Intervention: 400 mg of slow release ascorbic acid, 100 micrograms of organic selenium, 200 mg of D‐alpha‐tocopheryl acetate and 30 mg of beta‐carotene daily for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3042874

Group type: EXPERIMENTAL
Intervention: Dexamethasone (initial dose, 3 mg/kg; total, 11.4 mg/kg per 48 h)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 38
Study: 30915444

Group type: EXPERIMENTAL
Intervention: Higher intake of α- and β-carotene
Number of subjects: 5488

Group type: EXPERIMENTAL
Intervention: Higher intake of lutein plus zeaxanthin (L + Z)
Number of subjects: 5488

Group type: EXPERIMENTAL
Intervention: Higher intake of α-tocopherol
Number of subjects: 5488
Study: 28370447

Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (45 mg/10 mg twice daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 25452049

Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine or hydromorphone
Number of subjects: 139
Study: 23276118

Group type: EXPERIMENTAL
Intervention: Mindfulness self-training intervention group
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study: 21740445

Group type: EXPERIMENTAL
Intervention: Gamma irradiation (60 Gy in daily increments of 2 Gy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Composite resin restoration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amalgam restoration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonirradiated teeth
Number of subjects: 60
Study: 18556080

Group type: COMPARATOR
Intervention: 8 Gy in single fraction
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 30 Gy in 10 fractions
Number of subjects: 160
Study: 16607109

Group type: EXPERIMENTAL
Intervention: Ultralow-dose transdermal estradiol at 0.014 mg/d
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 14682655

Group type: EXPERIMENTAL
Intervention: Oxalate desensitizing agent
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 87
Study: 10953672

Group type: EXPERIMENTAL
Intervention: Cereal-based foods (chapatti, idli, poori) containing 50 g carbohydrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference glucose load (50 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cereal-based foods (GI values)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro starch digestibility
Number of subjects: 0
Study: 9317197

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8363067

Group type: COMPARATOR
Intervention: General anesthesia followed by intravenous morphine (GA)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia followed by epidural fentanyl (RA)
Number of subjects: 95

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (RA)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both groups (GA and RA)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Patients who developed postoperative arterial thrombosis
Number of subjects: 95
Study: 3539618

Group type: EXPERIMENTAL
Intervention: Metoprolol 15 mg i.v. + 50 mg q.i.d. orally
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30120066

Group type: EXPERIMENTAL
Intervention: Cobitolimod
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 28318397

Group type: EXPERIMENTAL
Intervention: Multi-macronutrient shake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting period of 8 hours
Number of subjects: 0
Study: 26550787

Group type: EXPERIMENTAL
Intervention: Bone scan with SPECT/CT
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (diagnostic blocks based on clinical diagnosis)
Number of subjects: 80
Study: 24320469

Group type: EXPERIMENTAL
Intervention: Proposed automatic localization algorithm using weighted Hough transform and constrained probabilistic boosting tree
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual measurements
Number of subjects: 0
Study: 20205349

Group type: EXPERIMENTAL
Intervention: Long-pulsed dye laser (LPDL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 40
Study: 18418017

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Preoperative radiochemotherapy (RCT)
Number of subjects: 32
Study: 16830315

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12028324

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 2676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2676
Study: 10494048

Group type: EXPERIMENTAL
Intervention: Lithium (Li; 31 patients)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ; 28 patients)
Number of subjects: 59
Study: 8983620

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall tolerance
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Vasovagal reactions
Number of subjects: 103
Study: 1837931

Group type: EXPERIMENTAL
Intervention: 0.5 mg nebulized ipratropium bromide
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.0 mg nebulized ipratropium bromide
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (5 mg) administered 2 hours after ipratropium
Number of subjects: 32
Study: 7026254

Group type: EXPERIMENTAL
Intervention: Ciramadol 20 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ciramadol 60 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pentazocine 50 mg
Number of subjects: 46
Study: 30776295

Group type: EXPERIMENTAL
Intervention: Nurse-led preventive, complex psychological intervention (promotion of a therapeutic ICU environment, 3 stress support sessions, relaxation and recovery program)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1458

Group type: COMPARATOR
Intervention: Nurse-led preventive, complex psychological intervention vs. usual care
Number of subjects: 1458
Study: 28277402

Group type: EXPERIMENTAL
Intervention: Rehabilitation algorithm (RA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: General rehabilitation protocol (RP)
Number of subjects: 48
Study: 26854974

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 24320560

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl 1 μg/kg
Number of subjects: 100
Study: 22044044

Group type: EXPERIMENTAL
Intervention: Oral antioxidants (AOs) treatment with α‐lipoic acid at 400 mg/day in association with genistein and vitamins
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19387424

Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5‐1.8 mg/kg per day)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Atomoxetine responders
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Combined cohort of ADHD children
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Caucasian subgroup
Number of subjects: 265
Study: 17204208

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) and interferon
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study: 12903414

Group type: EXPERIMENTAL
Intervention: Preoperative phenoxybenzamine (group P)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neostigmine (group N)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both phenoxybenzamine and neostigmine (group U)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (without drugs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neostigmine (when urinary retention happened)
Number of subjects: 80
Study: 9233529

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 on day 1 and oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Paclitaxel 160 mg/m2 on day 5 (schedule B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 on day 1 with oral etoposide 100 mg daily on days 1 to 5 (schedule A)
Number of subjects: 49
Study: 1345132

Group type: EXPERIMENTAL
Intervention: Low dose heparin (50 units/kg IV immediately after antivenom, followed by continuous infusion of 10 units/kg/hour for 24 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Antivenom alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low dose heparin
Number of subjects: 20
Study: 3549872

Group type: COMPARATOR
Intervention: Piracetam 2 X 3 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Piracetam 2 X 12 g
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30329199

Group type: EXPERIMENTAL
Intervention: Study drug (0.5 mg tyrothricin, 1.0 mg benzalkonium chloride, and 1.5 mg benzocaine)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 27782838

Group type: EXPERIMENTAL
Intervention: High parental involvement
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Medium parental involvement
Number of subjects: 347

Group type: COMPARATOR
Intervention: Low/no parental involvement
Number of subjects: 347
Study: 25042199

Group type: EXPERIMENTAL
Intervention: Siltuximab (11 mg/kg intravenous infusion every 3 weeks)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Siltuximab
Number of subjects: 79
Study: 22397837

Group type: EXPERIMENTAL
Intervention: High-flavanol chocolate containing maltitol (266 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-flavanol chocolate with sucrose (251 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-flavanol chocolate with sucrose (48 mg)
Number of subjects: 15
Study: 19905846

Group type: EXPERIMENTAL
Intervention: Bonded rapid maxillary expander (RME) followed by a removable maintenance plate and a transpalatal arch
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 500
Study: 18245199

Group type: EXPERIMENTAL
Intervention: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON
Number of subjects: 38

Group type: COMPARATOR
Intervention: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Atrial pacing lower rate 70 ppm and prevention and ATP therapies ON with septal lead placement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Atrial pacing lower rate 34 ppm and prevention and ATP therapies OFF with septal lead placement
Number of subjects: 38
Study: 16193675

Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injections (20 units in one single injection)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Botulinum toxin‐A injections
Number of subjects: 36
Study: 12956915

Group type: EXPERIMENTAL
Intervention: 4 ml of two per cent lignocaine and adrenaline 1:200000 with 1500 IU hyaluronidase
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 ml of two per cent lignocaine and adrenaline 1:200000
Number of subjects: 40
Study: 10384194

Group type: EXPERIMENTAL
Intervention: Bicaval technique
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 201
Study: 8698355

Group type: EXPERIMENTAL
Intervention: 3 MIU interferon alpha‐2a
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 1 MIU interferon alpha‐2a
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 2070654

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil and pyruvic acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: pyruvic acid alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5 percent 5‐fluorouracil cream
Number of subjects: 12
Study: 29536456

Group type: EXPERIMENTAL
Intervention: Sternal Talon
Number of subjects: 338

Group type: COMPARATOR
Intervention: Wire cerclage
Number of subjects: 338
Study: 27569737

Group type: EXPERIMENTAL
Intervention: Single dose of intravenous ibuprofen injection (0.2g, 0.4g, 0.8g) administered as a 30-minute IV infusion.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple doses of intravenous ibuprofen (0.4g every 6 hours for 9 doses).
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tolerability assessment of intravenous ibuprofen.
Number of subjects: 12
Study: 24576858

Group type: COMPARATOR
Intervention: Control trial (CON)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhalation of fast‐acting β2‐agonist (BD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sham to the hyperpnea (SHAM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperpnea challenge (BC)
Number of subjects: 17
Study: 22958874

Group type: EXPERIMENTAL
Intervention: 60 mg dextromethorphan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (diphenhydramine)
Number of subjects: 0
Study: 20189608

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 65
Study: 18514865

Group type: EXPERIMENTAL
Intervention: Multimodal oral pain medication protocol including preemptive oral analgesics, epidural anesthesia, pericapsular analgesic injection, and postoperative analgesia without parenteral opioids
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Multimodal oral pain medication protocol
Number of subjects: 70
Study: 16230877

Group type: EXPERIMENTAL
Intervention: niacin extended-release/lovastatin 1000/40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: atorvastatin 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: simvastatin 10 mg and 20 mg
Number of subjects: 0
Study: 12967694

Group type: EXPERIMENTAL
Intervention: Antihypertensive medications
Number of subjects: 2535
Study: 10919590

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 8706296

Group type: EXPERIMENTAL
Intervention: Intravenous beta-endorphin 5 mg/50 ml
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 6
Study: 1796228

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DEC 3 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg and DEC 3 mg/kg (twice a year)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Microfilaricidal drugs
Number of subjects: 58
Study: 6849786

Group type: EXPERIMENTAL
Intervention: Solpadeine (paracetamol with codeine and caffeine)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Panadol (paracetamol alone)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Paramax (paracetamol with metoclopramide)
Number of subjects: 4
Study: 31251709

Group type: EXPERIMENTAL
Intervention: Hypnosis group (HG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study: 28621820

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 132
Study: 26660768

Group type: EXPERIMENTAL
Intervention: Health Improvement Project for Teens (HIPTeens)
Number of subjects: 0
Study: 25261884

Group type: EXPERIMENTAL
Intervention: RENEW weight loss intervention
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: RENEW weight loss intervention (responder sites)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control condition (treatment as usual)
Number of subjects: 136
Study: 23101771

Group type: EXPERIMENTAL
Intervention: AWS with its tip inserted into the vallecula for indirect elevation of the epiglottis (Group AWS-I; n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AWS with its tip positioned posterior to the epiglottis for direct elevation of the epiglottis (Group AWS-D; n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group Mac; n = 30)
Number of subjects: 90
Study: 19767268

Group type: EXPERIMENTAL
Intervention: 30‐s TV ad simulation
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Billboard simulation
Number of subjects: 426

Group type: COMPARATOR
Intervention: No-information condition
Number of subjects: 426
Study: 17638634

Group type: EXPERIMENTAL
Intervention: Bisacodyl suppository
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15614010

Group type: EXPERIMENTAL
Intervention: Nabumetone (NSAID)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12173729

Group type: EXPERIMENTAL
Intervention: Miglitol 25 mg t.i.d.
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg t.i.d.
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg t.i.d.
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Miglitol 200 mg t.i.d.
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 468
Study: 9452226

Group type: EXPERIMENTAL
Intervention: 8-drugs-in-1-day (8-in-1) chemotherapy followed by radiotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Craniospinal radiotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Spinal radiotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 8 cycles of chemotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Relapse at primary site
Number of subjects: 18
Study: 7884950

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8
Number of subjects: 3404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3404

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant treatment
Number of subjects: 3404
Study: 2203215

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 192808

Group type: EXPERIMENTAL
Intervention: Intravenous adenine arabinoside (ara‐A)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 13
Study: 30739540

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) plus routine COPD medical treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine COPD medical treatment
Number of subjects: 42
Study: 30928442

Group type: EXPERIMENTAL
Intervention: Pre-dilatation (pre-BAV)
Number of subjects: 171

Group type: COMPARATOR
Intervention: No pre-dilatation (no-BAV)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study: 29197413

Group type: EXPERIMENTAL
Intervention: Early initiation of NOAC therapy (≤ 4 days after stroke onset)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Delayed initiation of NOAC therapy (≥ 5-10 days after stroke onset)
Number of subjects: 3000